Myelin-oligodendrocyte glycoprotein antibodies have been reported in a few NMO-IgG/AQP4-antibody seronegative patients with NMO [19,20,21]; it is reasonable to expect that novel antibodies will be identified in other NMO seronegative patients. This evidence concerns the gene MOG and neuromyelitis optica.